The chemo-free combo of Ribo+Let+trastuzumab led to mOFS 30.4 months, good ORR, and minimal cardiac toxicity in this ph2 1L Korean study. #ASCO25 @oncoalert.bsky.social

Pleased to be part of these elections!

In her Keynote Lecture at #ESMOBreast25, @loisher.bsky.social considers the question of who truly benefits from #immunotherapy in #BreastCancer, noting that success hinges on careful definition of responsive patient subgroups. Full article in the #ESMODailyReporter 🔗 ow.ly/rtbo50VSyiN

DIAmOND Trial at ESMO Breast 2025 Shows Activity of Durvalumab and Tremelimumab in Trastuzumab-Resistant HER2+ Breast Cancer @myesmo.bsky.social @loisher.bsky.social oncodaily.com/science/diam... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DIAmOND #ESMOBreast25

🎈🎈🎈news day for #HER2 pos #breastcancer. Will look fwd to seeing the HR and comparable toxicity profiles www.astrazeneca.com/media-centre...

Does the timing of neoadjuvant nivolumab initiation affect outcomes in early-stage triple-negative breast cancer? A phase II study led by Dr. Sherene Loi explores this critical question. Read more: ascopost.com/news/march-2... #TripleNegativeBreastCancer #Immunotherapy

Dr. Janni reviews ongoing ctDNA trials w/de-escalation, escalation. Starts with historical perspective that attempts to use CT/body imaging for early disease recurrence did NOT improve overall survival, only increased detection of recurrence (lead time bias). #SGBCC2025

#SGBCC2025 - The 19th St.Gallen International #BreastCancer Conference 2025 is almost here!💡 Key BIG 🔬 experts like Drs. Giuseppe Curigliano, @loisher.bsky.social, @tanjaspanic.bsky.social, & more will be there. Don't miss their insights! @oncoalert.bsky.social #bcsm

@thelancet.bsky.social the Lancet summit for cancer control in China 🇨🇳 Great discussion for #breastcancer #lungcancer #GIcancers

Many good things to say on this story @oncoalert.bsky.social @naturemedicine.bsky.social: 1) serious biomarker work from a pharma-sponsored trial👏👏 2) a tumor historically consid cold 🥶can respond to aPD1 🤩3) we need to redefine ER+ disease to enable personalized treatm✍️

🚩pleased to share our latest "Genomic Characterisation and Prognostic Significance of HER2–Low, HR+, Early #Breastcancer From the BIG 1-98 and SOFT Clinical Trials" #bcsm using centrally reviewed HER2 IHC from 2 large clinical trials #IBCSG @oncoalert.bsky.social 👏 ascopubs.org/doi/10.1200/...

🎈our recent collaborative review on “Complexities of Cancer” highlighted here 👏👏👏 🙏 @cp-cell.bsky.social as well as many other seminal articles- well worth a look 👀 @oncoalert.bsky.social

Remembering Jose Baselga and the superstar 👏⭐️ he was

summary CM-7FL @oncoalert.bsky.social @naturemedicine.bsky.social link: rdcu.be/d8Cw4. Here Nivo ⬆️ pCR rates in high grade HR+ BC. Increasing pCR rates in this subtype is HARD! PD-L1+ & #TIL higher pCR. This study will change how we think about HR+BC- some are immunogenic & need PD-1i with chemo

🎈Adjuvant Atezo for fully resected #TNBC #breastcancer is of NO benefit. We’ll see soon results from SWOG trial in re post neoadjuvant (w/o IO). Exposure to antigen and draining LN seems v. important for ICB efficacy. @oncoalert.bsky.social #bcsm

➡️➡️ very exciting news for estrogen receptor + #breastcancer- a subset is very immunogenic - this data changes the way we think about T cell immunosurveillance in this BC subtype 👏👏👏

📌 Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges 👉🏻 sciencedirect.com/science/articl… @ilanaschlam.bsky.social @loisher.bsky.social @oncoalert.bsky.social

Looking fwd to the joint annual meeting of 🇯🇵 #jcog #kbcs 🇰🇷#tibcs 🇹🇼 and @BCTrialsANZ 🇦🇺 in #nagoya #breastcancer trials

Great fun discussing #breastcsncer #immunotherapy in #japan #nagoya 🙏

We are incredibly proud to announce that five Peter Mac researchers have been named in Clarivate's top 1% most cited researchers worldwide for 2024. Read more: www.petermac.org/about-us/new...

HNY everyone! Our latest review @natrevcancer.bsky.social on the #breastcancer immune microenvironment is pinned here. Looking fwd to a very exciting 2025. rdcu.be/d51vW

#sabcs24 HR+HER2+ #breastcancer now finally its own entity 👏👏👏

#sabcs24 State of the Art session speakers Immune bio markers #til thanks to @balkolab @psharmab